MD3519398T2 - Compus de piridină - Google Patents

Compus de piridină

Info

Publication number
MD3519398T2
MD3519398T2 MDE20190863T MDE20190863T MD3519398T2 MD 3519398 T2 MD3519398 T2 MD 3519398T2 MD E20190863 T MDE20190863 T MD E20190863T MD E20190863 T MDE20190863 T MD E20190863T MD 3519398 T2 MD3519398 T2 MD 3519398T2
Authority
MD
Moldova
Prior art keywords
pharmaceutically acceptable
acceptable salts
relates
pyridine compound
compound
Prior art date
Application number
MDE20190863T
Other languages
English (en)
Inventor
Hiroaki Inagaki
Yoshihiro Shibata
Hidenori Namiki
Hideaki Kageji
Kiyoshi Nakayama
Yasuyuki Kaneta
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MD3519398T2 publication Critical patent/MD3519398T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Prezenta invenţie se referă la un compus care are activitate inhibitorie selectivă a RET kinază şi sărurile acceptate farmaceutic. Această invenţie se referă, de asemenea, la metode de fabricare a unor astfel de compuşi şi a compoziţiilor farmaceutice care conţin astfel de compuşi utile în tratamentul bolilor cum ar fi cancerul.În special un compus reprezentat de formula generală (I), definită aici:sau sărurile acceptate farmaceutic
MDE20190863T 2016-09-29 2017-09-28 Compus de piridină MD3519398T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
MD3519398T2 true MD3519398T2 (ro) 2021-05-31

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190863T MD3519398T2 (ro) 2016-09-29 2017-09-28 Compus de piridină

Country Status (32)

Country Link
US (2) US10851092B2 (ro)
EP (2) EP3519398B1 (ro)
JP (2) JP2018052878A (ro)
KR (1) KR102520543B1 (ro)
CN (2) CN113788824A (ro)
AU (2) AU2017335242C1 (ro)
BR (1) BR112019006047A2 (ro)
CA (1) CA3035860A1 (ro)
CL (1) CL2019000844A1 (ro)
CO (1) CO2019004034A2 (ro)
CY (1) CY1123988T1 (ro)
DK (1) DK3519398T3 (ro)
EA (1) EA037103B1 (ro)
EC (1) ECSP19030134A (ro)
ES (1) ES2868748T3 (ro)
HR (1) HRP20210447T1 (ro)
HU (1) HUE054824T2 (ro)
IL (1) IL265630B (ro)
LT (1) LT3519398T (ro)
MA (2) MA46337B1 (ro)
MD (1) MD3519398T2 (ro)
MX (1) MX2019003747A (ro)
PE (1) PE20190805A1 (ro)
PH (1) PH12019500480A1 (ro)
PL (1) PL3519398T3 (ro)
PT (1) PT3519398T (ro)
RS (1) RS61640B1 (ro)
SG (1) SG11201901937WA (ro)
SI (1) SI3519398T1 (ro)
UA (1) UA123964C2 (ro)
WO (1) WO2018060714A1 (ro)
ZA (1) ZA201902232B (ro)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3371171T (lt) 2015-11-02 2024-01-10 Blueprint Medicines Corporation Ret inhibitoriai
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
AU2020389184A1 (en) * 2019-11-18 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Combination drug
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP7461605B2 (ja) 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
CA3234317A1 (en) 2021-10-22 2023-12-14 Wa Xian Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
US20090076075A1 (en) 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CN102333765B (zh) * 2009-02-27 2015-01-14 帝人制药株式会社 基于使用过渡金属催化剂的偶联法的苯基取代杂环衍生物的制造方法
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
HUE029094T2 (hu) 2009-08-25 2017-02-28 Abraxis Bioscience Llc Kombinációs terápia egy taxánt és egy albumint tartalmazó nanorészecskéket magába foglaló készítménnyel
AU2011242689B2 (en) 2010-04-23 2015-09-17 Kineta, Inc. Anti-viral compounds
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
ME02664B (me) 2013-03-15 2017-06-20 Glaxosmithkline Ip Dev Ltd Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze
SG11201601341QA (en) * 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015163435A1 (ja) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規2-アミノ-ピリジン及び2-アミノ-ピリミジン誘導体及びその医薬用途
CN107074768B (zh) * 2014-09-10 2019-12-10 葛兰素史克知识产权发展有限公司 作为转染重排(ret)激酶抑制剂的吡啶酮衍生物
BR112017004897A2 (pt) * 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (en) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
HUE054824T2 (hu) 2021-10-28
EA201990833A1 (ru) 2019-10-31
ES2868748T3 (es) 2021-10-21
CY1123988T1 (el) 2022-05-27
AU2017335242B2 (en) 2021-08-19
ZA201902232B (en) 2022-12-21
KR102520543B1 (ko) 2023-04-10
JP2019534871A (ja) 2019-12-05
MA54910A (fr) 2022-04-13
MA46337B1 (fr) 2021-04-30
MA46337A (fr) 2019-08-07
EA037103B1 (ru) 2021-02-05
PH12019500480A1 (en) 2019-08-05
US10851092B2 (en) 2020-12-01
UA123964C2 (uk) 2021-06-30
SI3519398T1 (sl) 2021-07-30
PL3519398T3 (pl) 2021-06-28
JP7098609B2 (ja) 2022-07-11
BR112019006047A2 (pt) 2019-06-25
CN110036007B (zh) 2021-10-15
SG11201901937WA (en) 2019-04-29
AU2017335242A1 (en) 2019-05-02
HRP20210447T1 (hr) 2021-07-23
WO2018060714A1 (en) 2018-04-05
PT3519398T (pt) 2021-03-24
CO2019004034A2 (es) 2019-07-10
CN113788824A (zh) 2021-12-14
MX2019003747A (es) 2019-09-19
DK3519398T3 (da) 2021-03-29
CL2019000844A1 (es) 2019-06-07
CN110036007A (zh) 2019-07-19
ECSP19030134A (es) 2019-08-30
PE20190805A1 (es) 2019-06-10
CA3035860A1 (en) 2018-04-05
EP3519398A1 (en) 2019-08-07
RS61640B1 (sr) 2021-04-29
AU2021261899A1 (en) 2021-12-02
JP2018052878A (ja) 2018-04-05
US20210163464A1 (en) 2021-06-03
AU2017335242C1 (en) 2021-12-09
LT3519398T (lt) 2021-05-10
IL265630B (en) 2021-10-31
KR20190086442A (ko) 2019-07-22
EP3519398B1 (en) 2021-02-24
EP3828178A1 (en) 2021-06-02
IL265630A (en) 2019-05-30
US20200039974A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
MD3519398T2 (ro) Compus de piridină
MD3472167T2 (ro) Compuși heterociclici ca imunomodulatori
MX2023001876A (es) Derivados de rapamicina.
MD3394033T2 (ro) Compuși heterociclici ca imunomodulatori
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
MD3377488T2 (ro) Compuși heterociclici ca imunomodulatori
MD3269370T2 (ro) Compus pirimidinic condensat nou sau sare a acestuia
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201690752A1 (ru) Ингибиторы g12c kras
EA201991884A3 (ru) Ингибиторы g12c kras
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
TN2015000391A1 (en) Compounds and compositions for the treatment of parasitic diseases
EA201692000A1 (ru) Макроциклические производные пиридина
EA201692003A1 (ru) Макроциклические производные пиримидина
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
EA201692300A1 (ru) Производные карбоксамида
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды